The Kallikrein-Kinin System: Bradykinin, Angioedema, and Two Ways to Block It

Most people have never heard of the kallikrein-kinin system, yet it explains one of the more counterintuitive facts in medicine: why the standard treatments for allergic swelling — antihistamines, steroids, epinephrine — do absolutely nothing for the severe swelling of hereditary angioedema. The answer is that HAE swelling isn't histamine-driven at all. It's driven by a peptide called bradykinin.

The contact system in brief

The kallikrein-kinin system is part of the blood's contact (or "contact activation") system — a cascade of proteins that also interfaces with clotting and inflammation. The core sequence runs like this:

1. A precursor called prekallikrein is converted to the active enzyme plasma kallikrein.
2. Plasma kallikrein cleaves a large protein, high-molecular-weight kininogen (HMWK), releasing the small peptide bradykinin.
3. Bradykinin acts on the bradykinin B2 receptor on blood-vessel walls, making vessels dilate and — crucially — become leaky, letting fluid escape into tissues.

That fluid leak is what produces angioedema: deep, often disfiguring swelling of the skin, gut wall, and airway.

The brake: C1 esterase inhibitor

Left unchecked, this cascade would be dangerous, so the body restrains it. The main brake is C1 esterase inhibitor (C1-INH), a regulator that also reins in the complement system. C1-INH keeps plasma kallikrein and the contact system in check, limiting bradykinin production to appropriate amounts.

What goes wrong in hereditary angioedema

Most hereditary angioedema (HAE) is caused by a genetic deficiency or dysfunction of C1 esterase inhibitor (types 1 and 2). With the brake missing or broken, plasma kallikrein runs unchecked, bradykinin is overproduced, and patients suffer recurrent, unpredictable attacks of severe swelling. Airway attacks can be fatal. There is also a form of HAE with normal C1-INH (linked to factor XII and other mutations) that still funnels through excess bradykinin.

Because the mediator is bradykinin, not histamine, the entire allergy toolkit is ineffective — a distinction that is genuinely life-or-death to get right.

Two peptide drugs, two points of attack

Understanding the cascade shows exactly where a drug can intervene, and two approved peptides do so at different steps:

• Ecallantide inhibits plasma kallikrein — the enzyme that generates bradykinin. It blocks the pathway upstream, before bradykinin is even made. It is given by a healthcare professional because it can cause anaphylaxis.
• Icatibant blocks the bradykinin B2 receptor — the final step where bradykinin acts on blood vessels. It works downstream and can be self-injected at home.

The same logic underlies preventive HAE therapies: a monoclonal antibody (lanadelumab) and an oral drug (berotralstat) both target kallikrein to reduce attack frequency, and C1-inhibitor replacement products restore the missing brake directly.

Beyond angioedema

The kallikrein-kinin system also intersects with blood pressure and the ACE pathway — the enzyme ACE not only makes angiotensin II but also degrades bradykinin. This is why ACE-inhibitor blood-pressure drugs can occasionally cause a bradykinin-mediated angioedema of their own, and why they must be avoided in people with HAE.

Key takeaways

• The kallikrein-kinin (contact) system generates the peptide bradykinin, which makes blood vessels leaky and causes angioedema.
• C1 esterase inhibitor is the natural brake; its deficiency causes most hereditary angioedema.
• Because HAE swelling is bradykinin-mediated, antihistamines, steroids, and epinephrine don't work.
• Ecallantide blocks kallikrein (upstream); icatibant blocks the bradykinin B2 receptor (downstream).
• The ACE enzyme degrades bradykinin, which is why ACE inhibitors can trigger angioedema and are avoided in HAE.

This article is educational and does not constitute medical advice. Hereditary angioedema is managed by allergy/immunology specialists.